Gossamer Bio News

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

PDF Version SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini

Gossamer BioMay 14 12:00

12 Health Care Stocks Moving In Monday's After-Market Session

GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ

BenzingaMay 14 04:31

Chiesi Y Gossamer Bio Anuncian Una Colaboración Global Para Desarrollar Y Comercializar Seralutinib

Chiesi y Gossamer Bio anuncian una colaboración global transformadora para desarrollar y comercializar seralutinib en la hipertensión arterial pulmonar y otras indicaciones respiratorias Colaborac

PR NewswireMay 10 15:57

Chiesi Et Gossamer Bio Annoncent Une Collaboration Mondiale Transformatrice Pour Développer Et Commercialiser Le Séralutinib Pour L'hypertension Artérielle Pulmonaire Et D'autres Indications Respiratoires

Collaboration stratégique pour tirer parti de l'héritage de leadership dans les maladies respiratoires de Chiesi et de l'expertise de Gossamer Bio en matière de développement pour l'hypertension

PR NewswireMay 10 15:53

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini

Gossamer BioMay 10 12:00

Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth

TipRanksMay 10 00:45

Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush

Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush

Dow JonesMay 8 22:29

Wedbush: Reiterates Gossamer Bio (GOSS.US) rating and adjusted from superior to superior market rating, with a target price of $4.00.

Wedbush: Reiterates Gossamer Bio (GOSS.US) rating and adjusted from superior to superior market rating, with a target price of $4.00.

Zhitong FinanceMay 8 22:21

Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target

Wedbush analyst Laura Chico reiterates Gossamer Bio with a Outperform and maintains $4 price target.

Analyst UpgradesMay 8 22:19

Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating

TipRanksMay 8 11:55

Gossamer Bio: Q1 Earnings Snapshot

BarchartMay 8 05:15

Gossamer Bio Q1 EPS $(0.19) Misses $(0.18) Estimate

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 63.46 percent increase over losses of $(0.52

BenzingaMay 8 04:48

Gossamer Bio | 10-Q: Quarterly report

Futu NewsMay 8 04:08 · Announcements

Gossamer Bio Expects Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops, Expenditures Into 1H 2027 >GOSS

Gossamer Bio Expects Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops, Expenditures Into 1H 2027 >GOSS

Dow JonesMay 8 04:08

Gossamer Bio: Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 >GOSS

Gossamer Bio: Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 >GOSS

Dow JonesMay 8 04:07

Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS

Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS

Dow JonesMay 8 04:07

Gossamer Bio 1Q Loss/Shr 19c >GOSS

Gossamer Bio 1Q Loss/Shr 19c >GOSS

Dow JonesMay 8 04:01

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.

BusinesswireMay 8 04:01 · Earnings

Gossamer Bio and Chiesi Link for Pulmonary Hypertension Treatment

Yahoo FinanceMay 7 16:31

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)

TipRanksMay 7 08:21